Camitro Corporation

About

Camitro developed, marketed and sold, on a subscription basis, software for the analysis and prediction of a chemical compounds' properties prior to their application in a mammalian system, thereby allowing for a more cost-effective candidate selection process for drug developers. CHL led the Series B financing at the company. After securing several pharmaceutical clients, the company was sold to strategic buyer Arqule, Inc. (NASDAQ: ARQL).